ibrutinib

Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.

N-piperidine Ibrutinib is a potent BTK inhibitor with IC50s of 51.0 for WT BTK and 30.7 nM for C481S BTK respectively. N-piperidine Ibrutinib can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620. SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM.

Ibrutinib-D5 is a deuterium-labeled Ibrutinib. Ibrutinib (T1835) is an irreversible Btk inhibitor.

Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.

N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor, a BTK ligand, inhibits WT BTK and C481S BTK, which can be used to synthesize a range of PROTAC molecules.N-piperidine Ibrutinib hydrochloride has potential anticancer N-piperidine Ibrutinib hydrochloride has potential anticancer activity, inhibiting the growth and proliferation of cancer cells.

Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.

Ibrutinib Interm 0441 is a piperidine derivative with an amine protecting group and may be used in the preparation of biologically active compounds.

Ibrutinib-D5 (Standard) is a reference standard of Ibrutinib-D5 intended for quantitative analysis, quality control, and related biochemical research applications.

Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).

Ibrutinib-biotin, a probe consisting of Ibrutinib linked to biotin via a long-chain linker, has an IC50 of 0.755-1.02 nM for BTK.

PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)

Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton's tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.

(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.

Ibrutinib Impurity 11 is a byproduct of Ibrutinib.

Ibrutinib Impurity 23 is an impurity associated with Ibrutinib.

Ibrutinib Impurity 28 is an impurity associated with Ibrutinib.

Ibrutinib Impurity 14 is an impurity associated with Ibrutinib.

Ibrutinib (Standard) is a reference standard for research and analysis in studies involving Ibrutinib. Ibrutinib (PCI-32765) is a Bruton's tyrosine kinase (BTK) inhibitor (IC50=0.5 nM) with irreversible and selective properties. Ibrutinib blocks BTK to inhibit the proliferation and survival of B cells, and possesses antitumor activity, which can be used for the treatment of chronic lymphocytic leukemia, among others.

Dihydrodiol-Ibrutinib-[D5] (Standard) is a reference standard of Dihydrodiol-Ibrutinib-[D5] intended for quantitative analysis, quality control, and related biochemical research applications.

Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50: 1 nM). Remibrutinib has the potential for Chronic urticaria (CU) treatment.

IBT6A, an impurity of Ibrutinib, is a Btk inhibitor (IC50: 0.5 nM) that can be utilized in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.

(Rac)-IBT6A hydrochloride is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM).

IBT6A hydrochloride, an impurity of Ibrutinib, is relevant for synthesizing IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM).

(Rac)-IBT6A is a racemate of IBT6A, an impurity of Ibrutinib that can be utilized in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.